The INSPIRE-ASP Trial (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients) for Abdominal and Skin and Soft Tissue Infections The INSPIRE-ASP Trial (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients) for Abdominal and Skin and Soft Tissue Infections is a cluster-randomized trial to improve judicious antibiotic prescribing for non-critically ill hospitalized patients with abdominal infections or skin and soft tissue infections. Currently, over half of non-critically ill patients with one of these infections receive extended-spectrum antibiotics when less than 5% have an antibiotic-resistant pathogen. The goal of this trial is to advise physicians to prescribe standard- vs extended spectrum empiric antibiotics based on an algorithm that estimates each patient?s personalized probability of having an antibiotic-resistant infection. This personalized probability is based upon routinely-collected patient information in the electronic health record and local prevalence of resistant organisms in abdominal or skin and soft tissue infections. This trial will compare routine care under hospital-based antibiotic stewardship programs to the enhanced program using the predictive algorithm plus audit and feedback to reduce unnecessary empiric prescribing of extended-spectrum antibiotics. In our first aim, we will develop disease-specific prediction algorithms for abdominal infections and for skin and soft tissue infections. In our second aim, this predictive algorithm will be integrated into the computerized provider order entry (CPOE) system to prompt physicians when selected antibiotics are discordant with the estimated need for that antibiotic. Physicians will be prompted to use standard-spectrum antibiotics when the risk of an antibiotic-resistant infection is low. Sixty hospitals will be randomized to either routine care or the CPOE prompt intervention plus feedback. This 18-month study will evaluate ~53,000 patients with abdominal infections and ~37,000 patients with skin and soft tissue infections. This trial will evaluate the ability of a real-time risk calculator plus audit and feedback to reduce unnecessary extended-spectrum antibiotics while maintaining good clinical outcomes as measured by length- of-stay and transfer to an intensive care unit. These methods will be readily applicable to other electronic health record prescribing systems.

Public Health Relevance

The INSPIRE-ASP Trial (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients) for Abdominal and Skin and Soft Tissue Infections The INSPIRE-ASP Trial (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients) for Abdominal and Skin and Soft Tissue Infections is a randomized trial of 60 hospitals and nearly 100,000 infected patients to improve physicians? choice of antibiotics for hospitalized patients by reducing the unnecessary use of broad-spectrum antibiotics. This trial provides prescribers in half the hospitals with prescribing advice based on the probability that a patient is infected with antibiotic resistant bacteria. Unnecessary broad-spectrum antibiotics carry risks, and the goal of this trial is to limit their use to situations in which the patient is likely to require them, while maintaining excellent patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01AI153005-01
Application #
10018193
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Huntley, Clayton C
Project Start
2020-06-19
Project End
2025-05-31
Budget Start
2020-06-19
Budget End
2021-05-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Harvard Pilgrim Health Care, Inc.
Department
Type
DUNS #
071721088
City
Boston
State
MA
Country
United States
Zip Code
02215